|
|
Post by morangie777 on Feb 1, 2016 5:11:22 GMT
Is anyone following this Gene Therapy company? They have a cash position and quarterly burn rate that other biotechs dream of, yet what do we know about the future on the science side? The main candidate AVA101 Phase 2a trial for Wet AMD brought inconclusive or disappointing result mid 2015, then AAVL cancelled the plan to initiate a Phase2b trial and went back to preclinical studies instead. So what's ahead? Anything known about other products in the pipeline? They are trading so far below cash/book value, makes me at least want to take a closer look. Thanks! |
|
|
|
Post by JHam on Feb 1, 2016 12:51:27 GMT
Is anyone following this Gene Therapy company? They have a cash position and quarterly burn rate that other biotechs dream of, yet what do we know about the future on the science side? The main candidate AVA101 Phase 2a trial for Wet AMD brought inconclusive or disappointing result mid 2015, then AAVL cancelled the plan to initiate a Phase2b trial and went back to preclinical studies instead. So what's ahead? Anything known about other products in the pipeline? They are trading so far below cash/book value, makes me at least want to take a closer look. Thanks! Right on cue: finance.yahoo.com/news/avalanche-biotechnologies-annapurna-therapeutics-announce-120100653.html |
|
|
|
Post by morangie777 on Feb 1, 2016 16:28:13 GMT
Yes, interesting, I'll have to take a look at the details of this deal and what that company is about.
One high level take away from this is that Avalanche is not using its big cash pile for acquisitions, but rather tries to milk the SP for some more time. If they make more of this type of deals, expect further down pressure on the SP.
|
|
|
|
Post by harleyquinn on Feb 1, 2016 16:41:23 GMT
I know nothing about this one, but just glanced at the 5 year chart and it was at $60 about a year ago. Imagining the world of pain this decline represents.
|
|
|
|
Post by morangie777 on Feb 1, 2016 16:54:52 GMT
Having followed Ocata for a few years, you inevitably heard about Avalanche, since Dr. Schwartz, a key Ocata clinical trial investigator, is also a (the?) main Scientific person at Avalanche.
AAVLs market cap got boosted primarily through a partnership and financial backing by Regeneron. But this is now all falling apart quickly.
AAVL is clearly in a reboot phase. There is no clear path forward, yet, and the question remains, has the SP found a bottom. As we see today, there is always more room below..
|
|
